GB1187830A - Pharmaceutical Compositions comprising Polynucleotides - Google Patents

Pharmaceutical Compositions comprising Polynucleotides

Info

Publication number
GB1187830A
GB1187830A GB5707967A GB5707967A GB1187830A GB 1187830 A GB1187830 A GB 1187830A GB 5707967 A GB5707967 A GB 5707967A GB 5707967 A GB5707967 A GB 5707967A GB 1187830 A GB1187830 A GB 1187830A
Authority
GB
United Kingdom
Prior art keywords
polynucleotide
acid
interferon
dec
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5707967A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB1187830A publication Critical patent/GB1187830A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1,187,830. Pharmaceutical composition comprising polynucleotides. MERCK & CO. Inc. 15 Dec., 1967 [23 Dec., 1966; 25 May, 1967; 9 Aug., 1967; 22 Nov., 1967], No. 57079/67. Heading A5B. [Also in Division C3] A pharmaceutical composition for administration to persons and animals to induce in them the formation of interferon as a microbe-resisting substance, comprises a pharmaceutical carrier and a multistranded polynucleotide substantially free from proteins and other substances that inhibit the formation of interferon when the polynucleotide is administered to humans or animals or is added to a culture of living animal or human cells. The polynucleotide is suitably a polymer resulting from the complexing of two of the following homopolynucleotides:-polyadenylic acid, polyuridylic acid, polyinosinic acid, polycytidylic acid and cytidylcytidine; or is a ribonucleic acid that has been released by phenol from a ribonucleic acid complex elaborated by the growth of P. funiculosum; or the polynucleotide may be released from reovirus type 3 virions or the polynucleotide may be the isolated replicative intermediate form elaborated in living cells infected with a DNA or RNA virus.
GB5707967A 1966-12-23 1967-12-15 Pharmaceutical Compositions comprising Polynucleotides Expired GB1187830A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60413766A 1966-12-23 1966-12-23
US64111967A 1967-05-25 1967-05-25
US65930867A 1967-10-09 1967-10-09
US68493667A 1967-11-22 1967-11-22

Publications (1)

Publication Number Publication Date
GB1187830A true GB1187830A (en) 1970-04-15

Family

ID=27505067

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5707967A Expired GB1187830A (en) 1966-12-23 1967-12-15 Pharmaceutical Compositions comprising Polynucleotides

Country Status (7)

Country Link
BE (1) BE708470A (en)
DE (1) DE1617659C3 (en)
FR (2) FR1605535A (en)
GB (1) GB1187830A (en)
IE (1) IE31924B1 (en)
IL (1) IL29066A (en)
NL (1) NL159282B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216416A (en) * 1988-03-11 1989-10-11 Sandoz Ltd Immunostimulating compositions comprising nucleobase sources
WO1994015621A1 (en) * 1993-01-13 1994-07-21 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092875A1 (en) * 1970-06-26 1972-01-28 Maes Roland Interferon stimulants - dialkylaminoalkyl dextran-nucleic acid comple
EP0063657A1 (en) * 1981-04-29 1982-11-03 Merck & Co. Inc. Topical application of interferon inducers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046770A (en) * 1963-05-14 1966-10-26 James Harrison Stanton Therapeutic composition containing mycelial matter

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216416A (en) * 1988-03-11 1989-10-11 Sandoz Ltd Immunostimulating compositions comprising nucleobase sources
GB2216416B (en) * 1988-03-11 1992-06-24 Sandoz Ltd Nucleobase source for the stimulation of the immune system
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
WO1994015621A1 (en) * 1993-01-13 1994-07-21 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states

Also Published As

Publication number Publication date
DE1617659B2 (en) 1981-05-21
FR1605535A (en) 1979-02-23
NL6717585A (en) 1968-06-24
IE31924B1 (en) 1973-02-21
DE1617659C3 (en) 1982-01-21
DE1617659A1 (en) 1971-04-01
IE31924L (en) 1968-06-23
NL159282B (en) 1979-02-15
BE708470A (en) 1968-06-24
FR8373M (en) 1971-02-22
IL29066A (en) 1972-11-28

Similar Documents

Publication Publication Date Title
AU664717B2 (en) Stabilization of human interferon
DE69434121T2 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNE-REINFORCING THERAPY
GB1377435A (en) Triazolobenzodiazepines
WO1987004076A1 (en) Low dosage of interferon to enhance vaccine efficiency
Hilleman Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man
GB1294580A (en) New medicaments derived from nucleic acids, processes for their preparation and their use
Schooley Inhibition of erythropoietic stimulation by testosterone in polycythemic mice receiving anti-erythropoietin.
DE3570579D1 (en) Non-dusty blends of meals or flours with additives for use in fodder production
Kleinschmidt et al. Interferon induction with statolon in the intact animal
ATE33556T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ADENOSIN DERIVATIVES FOR TREATMENT OF TUMORS.
Larson et al. Influence of synthetic (poly I: C) and viral double-stranded ribonucleic acids on adenovirus 12 oncogenesis in hamsters
GB1187830A (en) Pharmaceutical Compositions comprising Polynucleotides
ATE65912T1 (en) MEDICINAL COMPOSITIONS OF REDUCED TOXICITY.
Larson et al. Influence of synthetic double-stranded ribonucleic acid (poly I: C) on SV40 viral oncogenesis and transplant tumor in hamsters
GB1362845A (en) Benzyl alcohol derivatives
GB1237352A (en) Substituted propylamines
CN103432569A (en) Recombinant human serum albumin-interferon alpha fusion protein water solution and preparation method thereof
JPS579711A (en) Preparation of prolonged release type complex
ES436179A1 (en) Physiological substances for intensifying the pharmacological effect of drugs
Breeze et al. Plasma levels of a long-acting oxytetracycline in cattle
Nishibe et al. Effects of phosphonoacetic acid on subacute myeloopticoneuropathy virus in vitro and in vivo
WO1987007836A3 (en) Medicament and medicinal composition for the treatment of infectious diseases due to viruses, as well as for the treatment of tumors
Potmesil et al. Inhibitory effect of polyinosinic: polycytidylic acid on the growth of transplantable mouse mammary carcinoma
SU487541A1 (en) The method of obtaining drugs of influenza virus
Ormai et al. Lymphocyte-mobilizing agents: Effects of polymethacrylic acid on transplantable lymphoma in rodents

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee